DOI: https://doi.org/10.26641/2307-0404.2018.3(part1).142349

Characteristics of hemostasis system and activity of trypsin-like blood enzymes in comorbid patients with chronic obstructive pulmonary disease and hypertension.

O. M. Kovalenko, V. V. Rodionova

Abstract


This work was aimed at studying the activity of the hemostasis system and trypsin-like blood enzymes (TLE) in patients with chronic obstructive pulmonary disease (COPD) and hypertension (H), depending on anthropometric, clinical features and smoking. The study included 87 patients. I group included 39 patients with COPD A – D, II-IV by GOLD and conco­mitant with H I-II stage, II group  – 38 patients with H I - II stage, and K group  – 10   apparently healthy persons. The study was conducted on the background of the use of standard basic therapy by patients from the 1st and 2nd groups in a stable period of disease. The degree of thrombocyte (tr) adhesion in I and II groups of patients was higher than in the K group. Both adhesive activity and the amount of tr in the I group was higher than in the II group. With positive status of smoking and increasing nicotine addiction in comorbid patients with COPD and H, the adhesive activity of tr increased. The level of the procoagulantive parameters of the plasma part of hemostasis in the two studied groups was not statistically different, but was higher than in the K group. Increased BMR and dyspnoea by the mMRS scale in group with COPD and H and increased age of patients with H led to the increase in the activity of plasma coagulation factors. In I and II groups, the increase in blood TLE was observed, which increased with the body weight, while in comorbid patients in the subgroup with FEV1≥50%, the incidence of COPD exacerbation additionaly effects the increase of TLE. In I group correlation between reduction of FEV1 with the decrease of TLE was revealed. In patients with COPD and AH activity of thrombocyte and plasma hemostasis, as well as trypsin-like blood enzymes, increases. Smoking, body weight gain and incidence of COPD exacerbation contribute to increased prothrombotic potential.

Keywords


chronic obstructive pulmonary disease; hypertension; hemostasis; activity of trypsin-like enzymes; smoking

References


Basanets AV, Dolinchuk LV. [Chronic Obstruc­tive Pulmonary Disease and Genetic predisposition]. Dovkillia ta zdorovia. 2017;1:4-10. Ukrainian.

Bugayenko VV, Slobodskoi VA, Tovstukha VV. [Co-morbid conditions: coronary heart disease and chro­nic obstructive pulmonary disease]. Ukr. kardiol. zhurnal. 2011;5:72-77. Russian.

Pertseva TO, Gashynova KYu, Vikliienko YuI. [Level α1-antitrypsin (AAT) in patients with chronic obstructive pulmonary disease (COPD)]. Medicni pers­pektivi. 2011;16(2):98-104. Ukrainian.

Rodionova VV, Karaseva OV. [The use of trip­sine - like blood activity as a marker of pulmonary fib­rosis severity]. Medicni perspektivi. 2018;23(2):50-56. Ukrainian.

Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion Mechanisms in pletelets. 2008;28:403-12.

Ramsey SD, Hobbs FD. Chronic obstructive pul­monary disease, risk factors, and outcome trials: сomparisons with сardiovas cular disease. Proc Am Thorac Soc. 2006;3:635-40.

Gimbrone M, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research. 2016;118:620-36.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. [Internet]; 2018. Available from: http://www.goldcopd.org.

Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of ar­terial hypertension of the European Society of Hyper­tension (ESH) and of the European Society of Cardiology (ESC). J. Hypertension. 2013;31:1281-357.

Chen W, Thomas J, Sadatsafavi M, Fitz Gerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic re­view and meta-analysis. Lancet Respir Med. [Internet]; 2015. Available from: https://www.ncbi.nlm.nih.gov/­pubmed/26208998.

World report on ageing and health. World Health Organization. [Internet]; 2015. Available from: http://www.who.int/ageing/publications/world-report-2015/en/.


GOST Style Citations


  1. Басанець А.В. Хронічне обструктивне за­хворювання легень та генетична схильність / А.В. Ба­санець, Н.В. Долінчук // Довкілля та здоров’я/ – 2017. – № 1. – С. 4-10.  https://cyberleninka.ru/article/n/hro­nichne-obstruktivne-zahvoryuvannya-legen-ta-genetichna-shilnist
  2. Бугаенко В.В. Коморбидные состояния: ише­мическая болезнь сердца и хроническое обструк­тивное заболевание легких / В.В. Бугаенко, В.А. Сло­бодский, В.В. Товстуха // Укр. кардіол. журнал. – 2011. – № 5. – С. 72-77. http://journal.ukrcardio.org/wp-content/uploads/2011/05/12_5_2011.pdf
  3. Перцева Т. О. Рівень α1-антитрипсину (ААТ) у хворих на хронічне  обструктивне захворювання легень (ХОЗЛ) / Т. О. Перцева, К. Ю. Гашинова, Ю. І. Віклієнко // Медичні перспективи. – 2011. – Т. 16, – № 2. – С. 98-104. https://docplayer.net/71147937-Klinichna-medicina-medichni-perspektivi-t-o-perceva-k-yu-gashinova-yu-i-vikliienko.htm
  4. Родіонова В.В. Використання показника трип­синоподібної активності крові як маркера тяжкості перебігу легеневого фіброзу / В.В. Родіонова, О.В. Ка­расьова // Медичні перспективи. – 2018. – Т. 23, № 2. – С. 50-56. https://doi.org/10.26641/2307-0404.2018.2(part1).129516
  5. Cell adhesion Mechanisms in pletelets / D. Varga-Szabo, I. Pleines, B. Nieswandt // Arteriosclerosis, Thro­mbosis, and Vascular Biology. - 2008. – Vol. 28. – P. 403 – 412. https://doi.org/10.1161/ATVBAHA.107.150474   
  6. Chronic obstructive pulmonary disease, risk factors, and outcome trials: сomparisons with сardiovas cular disease / S.D. Ramsey, F.D. Hobbs// Proc Am Thorac Soc. – 2006. – Vol. 3. – Р.635–640. https://www.ncbi.nlm.nih.gov/pubmed/16963547 
  7. Endothelial Cell Dysfunction and the Patho­bio­logy of Atherosclerosis / M. Gimbrone, G. García-Cardeña // Circulation Research.  – 2016. – Vol. 118.– P. 620-636.  https://doi.org/10.1161/CIRC­RESAHA.115.306301
  8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 report). http://www.gold­copd.org
  9. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Car­diology (ESC) / G. Mancia, R. Fagard, K.Narkiewicz [et al.] // J.  Hypertension. – 2013. – Vol. 31. – P. 1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  10. 10. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Lancet Respir Med / W. Chen, J. Thomas, M. Sadatsafavi, JM. FitzGerald // Lancet Respir Med. – 2015. https://www.ncbi.nlm.nih.gov/pub­med/26208998
  11.  World report on ageing and health // World Health Organization. – 2015. http://www.who.int/ageing/­publications/world-report-2015/en/




 

This work is licensed under a Creative Commons Attribution 4.0 International License